Focused Issues more

Vol 3, No 3 (September 2014): Systemic Treatment of Cutaneous and Mucosal Melanoma More >>
Vol 3, No 2 (June 2014): The Changing World of Drug Development More >>

Special Columns more







Figure 1:  Left: Daniel J. Sargent, PhD,Department of Biostatistics, Mayo Clinic, Rochester, MN, USA.  Right: Qian Shi, PhD,Cancer Center Statistics, Mayo P2C , Alliance GI, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA

Editor’s note: The special column “Statistics in Oncology Clinical Trials” is dedicated to providing state-of-the-art review or perspectives of statistical issues in oncology clinical trials. Our Chairs for the column are Dr. Daniel Sargent (Figure 1 Left) and Dr. Qian Shi( Figure 1 Right) , Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. The column is expected to convey statistical knowledge which is essential to trial design, conduct, and monitoring for a wide range of researchers in the oncology area. Through illustrations of the basic concepts, discussions of current debates and concerns in the literature, and highlights of evolutionary new developments, we are hoping to engage and strengthen the collaboration between statisticians and oncologists for conducting innovative clinical trials. Please follow the column and enjoy.

Vol 3, No 4 (December 2014)

Phase II design: history and evolution

Larry Rubinstein

Biometric Research Branch, NCI, Bethesda,MD, USA

Adaptive clinical trial designs inoncology

Yong Zang, J. Jack Lee

Department of Biostatistics, the University ofTexas MD Anderson Cancer Center, Houston, TX, USA

Vol 3, No 3 (September 2014) 

Biomarker based clinical trial design

Richard Simon

Biometric Research Branch, National CancerInstitute, Bethesda, MD, USA

On independent data monitoring committeesin oncology clinical trials

Janet Wittes, Mark Schactman

Statistics Collaborative Inc., Washington D.C.,20036, USA

 Vol 3, No 1 (March 2014)

Overview: biostatistician’s role inoncology clinical trials—strive for sound, efficient and practical studies

Qian Shi, Daniel J. Sargent

Department of Health Science Research, MayoClinic, Rochester, MN 55905, USA

The current design of oncology phase Iclinical trials: progressing from algorithms to statistical models

Thomas M. Braun

University of Michigan School of Public Health,1415 Washington Heights, Ann Arbor, MI, USA

Adaptive randomized phase II design forbiomarker threshold selection and independent evaluation

Lindsay A. Renfro1, Christina M. Coughlin2, AxelM. Grothey3, Daniel J. Sargent1

The special column “Statistics in OncologyClinical Trials” is dedicated to providing... More >>

Statistics in Oncology Clinical Trials

Phase II design: history and evolution
Larry Rubinstein
Adaptive clinical trial designs in oncology
Yong Zang, J. Jack Lee

Your Views

Widespread use of pemetrexed in oncology: has it turned it into a new drug?
Esther Una Cidon, Melania Varga, Tom Geldart, Pilar Alonso

Editorials

Can EGFR mutation status evolve with chemotherapy?
Eric S. Kim, David J. Stewart, Alok A. Khorana

Review Article

The spectrum of clinical trials aiming at personalizing medicine
Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois, Marie-Paule Sablin, Nicolas Servant, Xavier Paoletti
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine
Sumithra J. Mandrekar, Daniel J. Sargent
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
Sophie Doisneau-Sixou, Nadia Harbeck
Melanoma adjuvant therapy
Prashanth M. Thalanayar, Sanjiv S. Agarwala, Ahmad A. Tarhini
Genotyping of cutaneous melanoma
Isabella C. Glitza, Michael A. Davies
Treatment of KIT-mutated metastatic mucosal melanoma
Kevin B. Kim, Anas Alrwas

Original Article

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments
Laura E. Johnson, Jordan T. Becker, Jason A. Dubovsky, Brian M. Olson, Douglas G. McNeel

Review Articles

Prevention of colorectal cancer and dietary management
Ningqi Hou, Dezheng Huo, James J. Dignam
Stage II colon cancer
David N. Church, Rachel Midgley, David J. Kerr
Mining the ACCENT database: a review and update
Lindsay A. Renfro, Qian Shi, Daniel J. Sargent
Status of hepatocellular carcinoma in South Korea
Seung Kew Yoon, Hoo Geun Chun

Statistics in Oncology Clinical Trials

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
Lindsay A. Renfro, Christina M. Coughlin, Axel M. Grothey, Daniel J. Sargent
Adaptive clinical trial designs in oncology
Yong Zang, J. Jack Lee

Updates on Surgical Oncology

Clinical trials in lung cancer surgery and research cooperation
Wen-Zhao Zhong, Hao-Ran Zhai, Yi-Long Wu